It is of importance to understand the signaling pathways that regulates angiogenesis. It has been well known that angiogenic factors VEGF and bFGF induces the mitogenactivated protein kinase (MAPK) signaling pathway. MAPK is serine/threonine kinase and activated by various mitogen stimulation.
3) MAPK family kinases are divided into three members extracellular signal-regulated kinase (ERK) 1/2, cJun N-terminal kinase (JNK) 1, and p38 MAPK. Of the members, ERK predominantly is activated and p38 MAPK also is involved in migration of endothelial cells. 4, 5) In addition, it has been reported that phosphoinositol-3-kinase (PI3K)/AKT pathway in cancer cells play a critical role in modulating tumor growth and angiogenesis through expression of angiogenic growth factors. 6) Compound K (CK) is an intestinal metabolite isolated from ginseng protopanaxadiol saponins. We and others previously reported that CK induced apoptotic cell death in various cancer cells, suggesting its anti-cancer activity. [7] [8] [9] [10] However, there is no evidence on anti-angiogenic effect of CK until now. Thus, in our current study, we evaluated antiangiogenic effects of CK in vitro and in vivo. Angiogenesis was induced by basic fibroblast growth factor (bFGF) in human umbilical vein endothelial cells (HUVECs) and performed proliferation, migration and tube formation assays in vitro and Matrigel plug assay in vivo were performed to determine whether CK affects on bFGF-induced angiogenesis. Western blotting was performed with antibodies of p38 MAPK, AKT and cyclin D1. Cell Culture Human umbilical vein endothelial cells (HUVECs) were isolated from fresh human umbilical cord vein by collagenase treatment as described previously.
MATERIALS AND METHODS

Chemical and Reagents
11) The cells were cultured in M199 supplemented with 20% heatinactivated FBS, 3 ng/ml bFGF, 5 units/ml heparin and 100 units/ml antibiotic-antimycotic on 0.1% gelatin-coated flasks at 37°C in a humidified atmosphere containing 5% CO 2 . HUVECs were used within passages three to six.
Cytotoxicity and Proliferation Assays HUVECs (5ϫ 10 3 cells) were seeded onto 0.1% gelatin-coated 96-well microplates and incubated in a humidified incubator for 24 h. Cells were starved for 9 h in M199 containing 5% heat-inactivated FBS and then treated with various concentrations of CK. Then cytotoxicty of CK on the viability of HUVECs was evaluated by adding XTT working solution to the cells and the optical density was measured using microplate reader (Molecular Devices, Sunnyvale, CA, U.S.A.) at 450 nm. However, in proliferation assay, HUVECs were cultured in M199 containing 5% heat-inactivated FBS, 10 ng/ml bFGF and 5 units/ml heparin with or without CK for 48 h and XTT assay was performed as described in cytotoxicity assay.
Migration Assay Confluent HUVECs (3ϫ10 5 cells) monolayer was seeded onto 0.1% gelatin coated 6-well plates and "scratch" wounded using the tip of a universal 200 ml pipette tip. Then cells were treated with various concentrations of CK in M199 with 5% FBS, 10 ng/ml bFGF and 5 units/ml heparin. After 17 h incubation, the cell were rinsed with PBS, stained with Diff Quick solution and randomly chosen fields were photographed under a light microscope at ϫ100 magnification. The number of migrated cells was counted.
Tube Formation Assay In vitro differentiation assay of HUVECs on Matrigel into capillary-like tubes was performed as described previously. 12) Cells (3ϫ10 4 cells) were seeded onto Matrigel-coated 24-well plates, and CK were added in M199 with 1% FBS, 10 ng/ml bFGF and 5 units/ml heparin. After 7 h, cells were fixed with 4% paraformaldehyde, and randomly chosen fields were photographed under an Axiovert S 100 light microscope (Carl Zeiss, Thornwood, NY, U.S.A.) at 100ϫ magnification. Tube networks were quantified using NIH Scion image program. Experiments were repeated three times in triplicates.
Matrigel Plug Assay The Matrigel plug assay was performed as described previously.
13) Briefly, 6-week-old C57BL/6 mice (Daehan Biolink Co., Ltd., Daejeon, Korea) were given subcutaneous injection of 0.5 ml of growth factor reduced Matrigel containing CK (0.5 or 2.5 mg/kg), bFGF (300 ng/mouse) and heparin (5 units). After 7 d, mice were sacrificed, and the Matrigel plugs were removed. To indirectly quantify the formation of functional blood vessels, the amount of hemoglobin (Hb) was measured using the Drabkin reagent kit 525 (Sigma, St. Louis, MO, U.S.A.).
Western Blot Analysis HUVECs were starved in M199 containing 5% heat-inactivated FBS and exposed to various concentrations of CK for 12 h and then with bFGF (10 ng/ml) for 1 h. Cells were collected and incubated in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1 mM ethylenediaminetetraacetic acid (EDTA)), supplemented with protease inhibitors (10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml pepstatin A, and 1 mM of 4-(2-aminoethyl) benzenesulfonyl fluoride) and phosphatase inhibitors (1 mM NaF and 1 mM Na 3 VO 4 ) for 20 min on ice. Lysates were centrifuged at 14000 g for 20 min at 4°C. The lysates containing 20 mg of protein were fractionated by SDS-polyacrylamide gel electrophoresis (PAGE) and electrotransferred to a Hybond ECL transfer membrane (Amersham Pharmacia, Arlington Heights, IL, U.S.A.). The blocked membranes were then immunoblotted with primary antibodies (1 : 1000 dilution) of cyclin D1, p38 MAPK, phospho-p38 MAPK, phospho-AKT, AKT (Cell Signaling Tech., Beverly, MA, U.S.A.) and bactin (Sigma, St. Louis, MO, U.S.A.). For analysis of pigment epithelium derived factor (PEDF) expression, cells were cultured in conditioned medium, and culture supernatant was collected after drug treatment and subjected to Western blotting with anti-PEDF antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, U.S.A.). The proteins were visualized using enhanced chemiluminescence.
Statistical Analysis All values represent meansϮS.D. The statistically significant differences between bFGF control and CK treated group were calculated by the Student's t-test.
RESULTS
CK Inhibits bFGF-Induced Proliferation in HUVECs
To determine non-toxic concentration of CK against HUVECs, cytotoxicity assay was performed using cells exposed to various concentration of CK for 24 h by XTT assay. CK did not show any cytotoxicity up to 50 mM as shown in (Fig.  2A) . Thereafter, all experiment were performed at nontoxic concentrations of CK. Then, to assess the antiangiogenic activity of CK, we investigated bFGF-induced proliferation of HUVECs in vitro. HUVECs were exposed to various concentrations of CK with or without bFGF for 48 h. CK significantly inhibited the proliferation of bFGF-treated HUVECs in a concentration-dependent manner (Fig. 2B ) similar to VEGF inhibitor TNP-470 as a positive control.
14,15) Cyclin D1 as a mitogenic sensor and allosteric activator of CDK4/6, is one of the more frequently altered cell cycle regulators in cancers and so frequently overexpressed in cancers due to many factors including increased transcription, translation, and protein stability 16) and also cyclin D1 gene amplification was reported to promote abnormal endothelial cell proliferation and angiogenesis. 17) Consistently with anti-proliferative activity by CK in bFGF-treated HUVECs, Compound K inhibited the expression of cyclin D1 in bFGF-treated HUVECs in a concentration dependent manner by Western blotting (Fig. 2C) .
CK Inhibits bFGF-Induced Migration in HUVECs Endothelial cell migration is critical events for angiogenesis.
18) Thus, bFGF-induced migration assay was carried out to examine whether CK influence on migration of HUVECs in vitro. Results showed that CK treatment for 17 h resulted in 12.8 and 50.32% inhibition of bFGF-induced migration at concentration of 25 and 50 mM, respectively, while bFGF significantly enhanced migratory activity in untreated control (Fig. 3) .
CK Suppresses bFGF-Induced Tube Formation in HUVECs Stimulation of HUVECs seeded on the Matrigel by angiogenic growth factors such as VEGF and bFGF pro-motes differentiation to form capillary-like tubes. 19) We performed the tube formation assay to assess any specific effects of CK on this angiogenic processes. Our study showed that co-treatment with CK for 5 h resulted in 77.8 and 84.4% inhibition of bFGF-induced tube formation at concentrations of 25 and 50 mM, respectively, while bFGF significantly increased the number of tube formation in untreated control (Fig. 4) .
CK Inhibits bFGF-Induced Angiogenesis in Vivo To evaluate the in vivo anti-angiogenic activity of CK, Matrigel plug assay was performed. In the Matrigel plug assay, bFGFloaded plugs from mice exhibited reddish color indicating abundant red blood cells and therefore hemoglobin in the newly formed vasculature, whereas light yellowish color was shown in the CK/bFGF loaded plugs (Fig. 5A) . Similarly, CK significantly reduced the hemoglobin content to 7.4% of untreated control at 30 mM, respectively (Fig. 5B) .
CK Inhibits bFGF-Induced Angiogenesis via p38
MAPK and AKT in HUVECs
To analyze molecular mechanisms responsible for anti-angiognenic activity of CK, we measured the level of VEGF and PEDF, and evaluated the effect of CK on the phosphorylation of 38 MAPK, and AKT in bFGF treated HUVECs with or without CK. As shown in Fig. 6A , secreted level of VEGF was significantly decreased by CK treatment. In contrast, level of anti-angiogenic factor PEDF was significantly enhanced in a concentration-depen- dent manner (Fig. 6B) . In addition, CK downregulated the phosphorylation of p38 MAPK and AKT in bFGF treated HUVECs (Fig. 6C) . Consistently, p38 inhibitor SB202190 inihibited the phosphorylation of p38 and Akt, while ERK inhibitor PD98059 did not affect them in bFGF treated HUVECs.
DISCUSSION
Angiogenesis is the process involving the growth of new blood vessels from pre-existing vessels 20) and plays a critical role in neo-angiogenesis for growth, progression and metastasis in various cancers. 21) Many researchers have studied to develop the potential anti-angiogenic agents to modulate angiogenenic cascades including cell proliferation, migration and tube formation. 22) In recent few years, clinical trial with anti-angiogenic drugs or anti-angiogenic modalities targeting the VEGF-A/VEGFR-2 have shown survival benefit in cancer patients of advanced stage of malignancies. 23) In Oriental medicine, some medicinal herbs and natural compounds have been found to have anti-angiogenic as well as anti-cancer activities. Our group reported that naturally occurring gallotannin, penta-1,2,3,4,6-O-galloyl-b-D-glucose (PGG) inhibits the proliferation, migration and tube formation of endothelial cells. 24, 25) Likewise, anti-angiogenic activities by paonol, shikonin, campesterol, heyneanol A and 6-(1-oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone, Korean Angelica gigas and Kamikaekyuktang, Shiquandabutangjiaweibang and Bojungbangdoktang were demonstrated by our group. [26] [27] [28] [29] [30] [31] [32] [33] In the present study, we have investigated whether or not CK can inhibit bFGF-mediated angiogenesis and its related signaling pathways in HUVECs.
Ginseng Radix, the root of Panax ginseng C. A. MEYER, has been utilized as a traditional medicinal herb in Asian countries. Ginsenosides, a class of steroid glycosides and triterpene saponins, contained in Panax ginseng have been reported to exert a variety of biological activities targeting cancer, inflammation, allergy and diabetes. 34, 35) Recently, ginsenoside Rg3 inhibited VEGF-induced proliferation, tube formation and chemoinvasion in HUVECs, suggesting antiangiogenic activity of Rg3. 36) In contrast, other gisenoside compounds Rg1 and Re significantly promoted proliferation, migration and tube formation in HUVECs. 37, 38) Here, CK significantly inhibited the proliferation (Fig. 2B) , migration ( Fig. 3 ) and tube formation (Fig. 4) of bFGF-treated HUVECs, similar to the antiangiogenic pattern of ginsenoside Rg3. Furthermore, as suggested that cyclin D1 promotes abnormal endothelial cell proliferation and angiogenesis, CK attenuated the expression of cyclin D1 and also significantly reduced the level of VEGF in bFGF-treated HUVECs compared to untreated control, indicating the inhibitory effect of CK on the proliferation of HUVECs (Fig. 2C) . Consistently, CK significantly reduced the level of VEGF, a major angiogenic growth factor 39) and increased the level of PEDF, a potent anti-angiogenic factor 40) in HUVECs (Figs. 6A, B ). In addition, CK significantly suppressed the vascularization in bFGF-treated Matrigel plugs in mice by reducing the secreted level of hemoglobin (Fig. 5) in the new vessels. These findings indicate a potent anti-angiogenic effect of CK in vitro and in vivo.
It is well known that the activation of the mitogenactivated protein kinase signaling is importantly implicated in angiogenesis. 41) In this regard, many natural compounds inhibited angiogenesis by targeting the MAPK signaling pathway. PGG diminished ERK 1/2 and JNK phosphorylation and increased phospho-p38 MAPK in a dose-dependent manner in bFGF-treated HUVECs. 24) Wang and his colleagues reported that beta Escin, the major compound of Aesculus hippocastanum seed showed decreased activation of ERK 1/2 and p38 MAPK in human endothelial HUVECs and ECV304 cells. 42) Our study revealed that CK downregulated p38 MAPK in a concentration-dependent manner in bFGF treated HUVECs (Fig. 6C) , while activation of p38 MAPK mediates apoptosis in Compound K treated cancer cells. 43, 44) PI3K/AKT activation is another important signaling event to regulate angiogenesis. Natural compound thymoquinone from Eupatorium ayapana and apigenin from Dendranthema indicum have been reported their anti-angiogenic activities through suppression of AKT activation. 45, 46) Our study also showed that CK significantly suppressed bFGF-induced AKT activation in HUVECs. Considering the antitumor effect of CK at higher concentrations and antiangiogenic activity of CK at lower concentrations (below 50 mM) of CK, it is necessary for us to confirm in vivo antitumor activity and its molecular mechanisms on apoptosis and angiogenesis by using immunohistochemistry in the near future.
In conclusion, Compound K exerted anti-angiogenic activity via the inhibition of proliferation, migration, tube formation in in bFGF treated HUVECs, suppressed the neovascularization in Matrigel from mice and also downregulated p38 MAKP and AKT signaling pathways. Overall, our findings suggest that Compound K exhibits the potential for a potent cancer chemopreventive agent partly via anti-angiogenic activity.
